

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

Date: 18th October, 2017

To,
Bombay Stock Exchange Ltd.
Department of Corporate Services
25th Floor, P.J.Towers, Dalal Street,
Mumbai-400 001

Script ID : 506365

Subject : SUBMISSION OF COMPLIANCES UNDER SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

Dear Sirs,


We are enclosing herewith Quarterly Compliances pursuant to Securities And Exchange Board of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 for Quarter ended 30th September, 2017 as under -

1.	Regulation 33	Un-audited Quarterly Financial Results along with Statement of Assets And Liabilities for the Quarter ended 30/09/2017 along with Limited Review Report issued by our Auditors, M/s. VMD & Co., Chartered Accountant, Mumbai
2.		Outcome of the Board Meeting Held on 18/10/2017

You are requested to take this on your records.

Thanking You.
Yours Faithfully,

FOR CHEMO PHARMA LABORATORIES LIMITED


ASHOK SOMANI
DIRECTOR
(DIN NO. - 03063364)





LIMITED REVIEW REPORT

We have reviewed the accompanying Statement of unaudited financial results of **M/S CHEMO PHARMA LABORATORIES LTD.**, Mumbai for the quarter ended **30th September, 2017**. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors / committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagement to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with applicable Accounting Standards and other recognized accounting practices and polices has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

NO: C/02/1017
Dated: 10/10/2017
Place: MUMBAI

For M/s VMD & CO.
Chartered Accountants.
FRN: 125002W


CA AMIT GANPULE
PARTNER
MRN: 114222



CHEMO PHARMA LABORATORIES LIMITED

REGISTERED OFFICE: 5-KUMUD APARTMENT CO. OP. HSG. SOC. LTD., KARNIK ROAD, CHIKAN GHAR, KALYAN, DIST. THANE- 421301

• CORPORATE OFFICE- EMPIRE HOUSE, 3RD FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001

• TEL NO.: (022) 22078381, 22078382 • FAX NO.: (022)22074294

• CIN NO.: L99999MH1942PLC003556 • PAN NO.: AAACC2056K

WEBSITE: www.thechemopharmalaboratoriesltd.com

EMAIL ID: chemopharmalab@gmail.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED ON 30th SEPTEMBER, 2017

Sr. No.	Particulars	(Rupees in Thousand)					
		Quarter Ended			Six Months Ended		Year Ended
		30th Sept., 2017	30th June 2017	30th Sept., 2016	30th Sept., 2017	30th Sept., 2016	31st March 2017
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
I	Revenue from Operations						
II	Other Income	2,341	1,377	1,490	3,718	2,414	56,080
III	Total Revenue (I + II)	2,341	1,377	1,490	3,718	2,414	56,080
IV	Expenses						
	(1) Cost Materials consumed	-	-	-	-	-	-
	(2) Purchase of Stock-in-Trade	-	-	-	-	-	-
	(3) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-	-	-
	(4) Employee Benefits Expenses	520	244	191	764	381	805
	(5) Depreciation and Amortisation Expenses	-	-	-	-	-	-
	(6) Other Expenses (Any Item exceeding 10% of the Total Expenses relating to continuing Operations to be shown separately)	159	165	156	324	193	872
	i) Professional Charges	8	67	79	75	99	699
	ii) Share Registry Expenses	22	15	18	37	31	92
	iii) Annual Listing Fees	17	298	-	315	256	256
	(7) Finance Costs	-	-	-	-	-	-
	Total Expenses	725	789	444	1,515	960	2,724
V	Profit/(Loss) before Exceptional and Extra ordinary Items and tax (III - IV)	1,616	588	1,046	2,204	1,454	53,356
VI	Exceptional Items	-	-	-	-	-	-
VII	Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI)	1,616	588	1,046	2,204	1,454	53,356
VIII	Extra Ordinary Items	-	-	-	-	-	-
IX	Profit/(Loss) before Tax (VII-VIII)	1,616	588	1,046	2,204	1,454	53,356
X	Tax Expenses						
	(1) Current Tax	-	5,177	-	5,177	-	6,515
	(2) Deferred Tax	-	-	-	-	-	-
XI	Profit/(Loss) for the period from continuing operations (IX - X)	1,616	(4,589)	1,046	(2,974)	1,454	46,841
XII	Profit/(Loss) from discontinuing operations	-	-	-	-	-	-
XIII	Tax Expenses of discontinuing operations	-	-	-	-	-	-
XIV	Profit/(Loss) from discontinuing operations (after tax) (XII - XIII)	-	-	-	-	-	-
XV	Profit/(Loss) for the period (XI - XIV)	1,616	(4,589)	1,046	(2,974)	1,454	46,841
XVI	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss						
	B (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss						
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	1,616	(4,589)	1,046.00	(2,974)	1,454	46,841
XVIII	Earnings per Share :						
	(1) Basic	1.08	(3.05)	0.70	(1.98)	0.97	31.23
	(2) Diluted						



CHEMO PHARMA LABORATORIES LIMITED

REGISTERED OFFICE: 5-KUMUD APARTMENT CO. OP. HSG. SOC. LTD., KARNIK ROAD, CHIKAN GHAR, KALYAN, DIST. THANE- 421301

• CORPORATE OFFICE- EMPIRE HOUSE, 3RD FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001

• TEL NO.: (022) 22078381, 22078382 • FAX NO.: (022)22074294

• CIN NO.: L99999MH1942PLC003556 • PAN NO.: AAACC2056K

WEBSITE: www.thechemopharmalaboratoriesltd.com

EMAIL ID: chemopharmalab@gmail.com

Notes :

- 1 This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.
- 2 The above Un-Audited Financial Results for the Quarter and Six Months Ended 30.09.2017 have been reviewed by the Audit Committee in their Meeting held on 18.10.2017 and approved by the Board of Directors of its Meeting held on 18.10.2017. The Limited Review Report of Auditors M/s VMD & Co. was also taken on record by the Board in its Meeting.
- 3 The Company is not having any Subsidiary Company.
- 4 The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.

Place : Mumbai

Date : 18th October, 2017



For Chemo - Pharma Laboratories Limited

A handwritten signature in black ink, appearing to read 'Ashok Somani'.

Ashok Somani
Director

CHEMO PHARMA LABORATORIES LIMITED

REGISTERED OFFICE: 5-KUMUD APARTMENT CO. OP. HSG. SOC. LTD., KARNIK ROAD, CHIKAN GHAR, KALYAN, DIST. THANE- 421301

• CORPORATE OFFICE- EMPIRE HOUSE, 3RD FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001

• TEL NO.: (022) 22078381, 22078382 • FAX NO.: (022)22074294

• CIN NO.: L99999MH1942PLC003556 • PAN NO.: AAACC2056K

WEBSITE: www.thechemopharmalaboratoriesltd.com

EMAIL ID: chemopharmalab@gmail.com

STANDALONE STATEMENT OF ASSETS & LIABILITIES AS ON 30TH SEPTEBER, 2017 (Rupees in Thousands)

Sr. No.	PARTICULARS	As at 30.09.2017 RUPEES	As at 31.03.2017 RUPEES
A	<u>EQUITY AND LIABILITIES</u>		
1	SHAREHOLDERS' FUNDS		
	(a) Share Capital	15,000	15,000
	(b) Reserves and Surplus	82,253	85,226
	Sub Total - Shareholders' Funds	97,253	1,00,226
2	NON CURRENT LIABILITIES		
	(a) Other Long Term Liabilities	1,197	1,197
	Sub Total - Non- Current Liabilities	1,197	1,197
3	CURRENT LIABILITIES		
	(a) Other Current Liabilities	253	276
	(b) Short Term Provisions	-	5,491
	Sub Total - Current Liabilities	253	5,767
	TOTAL - EQUITY AND LIABILITIES	98,703	1,07,190
B	<u>ASSETS</u>		
1	NON CURRENT ASSETS		
	(a) Fixed Assets	99	94
	(b) Non Current Investment	187	187
	(c) Non Term Loan & Advances	-	-
	Sub Total - Non- Current Assets	286	281
2	CURRENT ASSETS		
	(a) Cash & Cash Equivalents	29,878	68,734
	(b) Short Term Loans and Advances	52,505	22,505
	(c) Short Term Loans and Advances	16,034	15,670
	Sub Total - Current Assets	98,417	1,06,909
	TOTAL - ASSETS	98,703	1,07,190

By Order of the Board
For Chemo - Pharma Laboratories Limited

Ashok Somani

Place : Mumbai
Date : 18th October, 2017



ASHOK SOMANI
DIRECTOR

CHEMO PHARMA LABORATORIES LIMITED

REGISTERED OFFICE: 5-KUMUD APARTMENT CO. OP. HSG. SOC. LTD., KARNIK ROAD, CHIKAN GHAR, KALYAN, DIST. THANE- 421301

• CORPORATE OFFICE- EMPIRE HOUSE, 3RD FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001

• TEL NO.: (022) 22078381, 22078382 • FAX NO.: (022)22074294

• CIN NO.: L99999MH1942PLC003556 • PAN NO.: AAACC2056K

WEBSITE: www.thechemopharmalaboratoriesltd.com

EMAIL ID: chemopharmalab@gmail.com

RECONCILIATION OF STANDLONE NET PROFIT FOR THE QUARTER ENDED 30TH SEPTEMBER, 2017

(Rs. In Thousand)

PARTICULARS	STANDLONE	
	UNAUDITED QUARTER ENDED 30.09.2017	AUDITED YEAR ENDED 31.03.2017
Reconciliation of Profit After Tax as reported earlier:		
Net Profit / (Loss) for the Period (as per AS)	1,616.00	53,356.00
Benefit / (Charge):		
Impact of Deferred Income (Government Grant) Amortized to Income	-	-
Impact of Fair Valuation of Financial Instruments	-	-
Impact of Actuarial Gain / Loss Taken OCI	-	-
Impact of Adjustment of Deferred Tax	-	-
Net Profit / (Loss) for the Period (as per AS)	1,616.00	53,356.00

For Chemo Pharma Laboratories Ltd.

Mumbai, 18th October, 2017



Ashok Somani

Ashok Somani
Director

CHEMO PHARMA LABORATORIES LIMITED

REGISTERED OFFICE: 5-KUMUD APARTMENT CO. OP. HSG. SOC. LTD., KARNIK ROAD, CHIKAN GHAR, KALYAN, DIST. THANE- 421301

• CORPORATE OFFICE- EMPIRE HOUSE, 3RD FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001

• TEL NO.: (022) 22078381, 22078382 • FAX NO.: (022)22074294

• CIN NO.: L99999MH1942PLC003556 • PAN NO.: AAACC2056K

WEBSITE: www.thechemopharmalaboratoriesltd.com

EMAIL ID: chemopharmalab@gmail.com

RECONCILIATION OF STANDLONE NET PROFIT FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2017

(Rs. In Thousand)

PARTICULARS	STANDLONE	
	UNAUDITED QUARTER ENDED 30.09.2017	UNAUDITED HALF YEAR ENDED 30.09.2017
Reconciliation of Profit After Tax as reported earlier:		
Net Profit / (Loss) for the Period (as per AS)	1,616.00	2,204.00
Benefit / (Charge):		
Impact of Deferred Income (Government Grant) Amortized to Income	-	-
Impact of Fair Valuation of Financial Instruments	-	-
Impact of Actuarial Gain / Loss Taken OCI	-	-
Impact of Adjustment of Deferred Tax	-	-
Net Profit / (Loss) for the Period (as per AS)	1,616.00	2,204.00

For Chemo Pharma Laboratories Ltd.



A handwritten signature in black ink, appearing to read 'Ashok Somani'.

Ashok Somani
Director

Mumbai, 18th October, 2017